-Amendment to the Claims-

1. (Currently amended) A compound of formula (1):



(1)

wherein the CH_2-C(=O)NH-benzyl-Q^1-Q^2-Q^3-Q^4 group is in the meta or para position; [[, and]]

R^1 and R^2 are independently selected from H and C_1-C_4 alkyl;

Q^1 is -$(CH_2)_n$-; ~~wherein~~

n is ~~an integer selected from~~ 0 or ~~and~~ 1;

Q^2 is ~~a group~~ selected from -NH-, -C(=O)NH-, -NHC(=O)-, -NH-C(=O)-NH-, and -SO_2NH-;

Q^3 is a single bond or a C_1-C_4 alkylene optionally substituted with OH;

Q^4 is selected from



, , and ,

wherein * represents the attachment point to Q^3; ~~and~~

R^3, R^4, R^5, R^6 and R^7 are independently selected from H, C_1-C_4 alkyl, phenyl, phenoxy, OR^8, SR^8, halo, CN, CF_3, OCF_3, $COOR^9$, $SO_2NR^8R^9$, $CONR^8R^9$, NR^8R^9, $NHCOR^9$ and CH_2-NHC(=O)NH-R^9; and

~~wherein~~ R^8 and R^9 are independently selected from H and ~~or~~ C_1-C_4 alkyl;

or ~~, if appropriate, their~~ a pharmaceutically acceptable salt, isomer, tautomer, solvate or isotopic variation ~~salts and/or isomers, tautomers, solvates or isotopic variations~~ thereof.

2. (Currently amended) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Q^1 is $(CH_2)_n$, ~~wherein~~ n is 0 and Q^2 is –SO_2NH- or ~~C(=O)NH-~~ -C(=O)NH-.

3. (Currently amended) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Q^1 is $(CH_2)_n$, ~~wherein~~ n is 1 and Q^2 is –NH-C(=O)- or -NH-C(=O)-NH-.

4. (Currently amended) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, ~~any one of claims 1 to 3~~ wherein Q^3 is a bond, $-CH_2-$, $-(CH_2)_2-$, $-C(CH_3)_2-CH_2-$, $-CH(CH_3)-CH(OH)-$ or ~~$CH_2-CH(CH_3)$~~ $-CH_2-CH(CH_3)-$.

5. (Currently amended) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, ~~any one of claims 1 to 4~~ wherein Q^4 is



; and

~~wherein~~ R^3, R^4, R^5, R^6 and R^7 are selected from H, C_1-C_4 alkyl, phenyl, phenoxy , OR^8, SR^8, halo, CF_3, OCF_3, $COOR^9$, $SO_2NR^8R^9$, $CONR^8R^9$, NHR^8R^9, $NHCOR^9$ [[,]] and CH_2-$NHC(=O)NH-R^9$; ~~and~~ provided that at least two of R^3 to R^7 are ~~represent~~ H.

6. (Currently amended) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, ~~any one of claims 1 to 5~~ wherein R^1 and R^2 are independently selected from H and CH_3.

7. (Currently amended) The (*R*,*R*)-stereoisomer of a compound according to claim 1 ~~any one of claims 1 to 6~~ or a pharmaceutically acceptable salt thereof.

8. (Currently amended) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, ~~any one of claims 1 to 7~~ wherein the CH_2-C(=O)NH-benzyl-Q^1-Q^2-Q^3-Q^4 group is in the meta position.

9. (Currently amended) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: ~~examples 1 to 26~~ *N*-(4-*tert*-butylbenzyl)-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl) phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide; *N*-(2-ethoxybenzyl)-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide;

4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl} amino)propyl]phenyl}acetyl)amino]methyl}-*N*-[4-(trifluoromethoxy)benzyl] benzamide;
N-(3,4-dichlorobenzyl)-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide;
N-[2-fluoro-5-(trifluoromethyl)benzyl]-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino] methyl}benzamide;
N-[3,5-bis(trifluoromethyl)benzyl]-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide;
4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl} amino)propyl]phenyl}acetyl)amino]methyl}-*N*-(4-phenoxybenzyl)benzamide;
N-(1,1-dimethyl-2-phenylethyl)-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide;
N-[2-(4-ethylphenyl)ethyl]-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide
N-[2-(4-chlorophenyl)ethyl]-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide;
N-[2-(4-ethoxyphenyl)ethyl]-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide;
N-[2-(1,1'-biphenyl-4-yl)ethyl]-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide;
4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl} amino)propyl]phenyl}acetyl)amino]methyl}-*N*-(4-hydroxy-3-methoxybenzyl) benzamide;
N-(1,1'-biphenyl-3-ylmethyl)-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide;
4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl} amino)propyl]phenyl}acetyl)amino]methyl}-*N*-[2-(3-methoxyphenyl)ethyl] benzamide;
N-[2-(3,4-dichlorophenyl)ethyl]-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide;
4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl} amino)propyl]phenyl}acetyl)amino]methyl}-*N*-[(2*S*)-2-phenylpropyl]benzamide;
4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl} amino)propyl]phenyl}acetyl)amino]methyl}-*N*-[(1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl]benzamide;
4-ethoxy-*N*-(4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl) phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl}benzyl)benzamide;

N-(4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl}benzyl)-1-naphthamide;
N-(4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl}benzyl)-2,2-diphenylacetamide;
N-(4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl}benzyl)-4-phenoxybenzamide;
N-{4-[(benzhydrylamino)methyl]benzyl}-2-{3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;
N-{3-[(benzylamino)sulfonyl]benzyl}-2-{3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;
2-{3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}-*N*-{4-[({[(3-phenoxybenzyl)amino]carbonyl}amino)methyl]benzyl}acetamide; and
N-(3,4-dimethoxybenzyl)-4-{[({3-[(2*R*)-2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methyl} benzamide.

10 - 11. (canceled)

12. (Currently amended) A method of treating a disease, disorder or condition in ~~treatment of~~ a mammal, ~~including a human being,~~ which method comprises administering to said mammal ~~with a β2 agonist including treating said mammal with~~ an effective amount of a compound of claim 1 ~~formula (1) as described in any one of claims 1 to 9~~ or ~~with~~ a pharmaceutically acceptable salt~~, derived form or composition~~ thereof, said disease, disorder or condition being selected from the group consisting of

- atopic asthma, non-atopic asthma, allergic asthma, atopic bronchial IgE-mediated asthma, bronchial asthma, essential asthma, true asthma, intrinsic asthma caused by pathophysiologic disturbances, extrinsic asthma caused by environmental factors, essential asthma of unknown or inapparent cause, bronchitic asthma, emphysematous asthma, exercise-induced asthma, allergen induced asthma, cold air induced asthma, occupational asthma, infective asthma caused by bacterial, fungal, protozoal, or viral infection, non-allergic asthma, incipient asthma, wheezy infant syndrome, bronchiolytis,
- chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema,
- chronic eosinophilic pneumonia, chronic obstructive pulmonary disease (COPD), COPD that includes chronic bronchitis, pulmonary emphysema not

associated with COPD, pulmonary emphysema associated with COPD, dyspnea not associated with COPD, dyspnea associated with COPD, COPD that is characterized by irreversible, progressive airways obstruction, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy, airways disease that is associated with pulmonary hypertension,

- chronic bronchitis, acute bronchitis, acute laryngotracheal bronchitis, arachidic bronchitis, catarrhal bronchitis, croupus bronchitis, dry bronchitis, infectious asthmatic bronchitis, productive bronchitis, staphylococcus bronchitis, streptococcal bronchitis, vesicular bronchitis,
- acute lung injury,
- cylindric bronchiectasis, sacculated bronchiectasis, fusiform bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, dry bronchiectasis, and follicular bronchiectasis.

13. (Currently amended) A pharmaceutical composition comprising a combination of a compound according to claim 1 ~~any one of claims 1 to 9~~ with a therapeutic agent selected from:

(a) 5-Lipoxygenase (5-LO) inhibitors or 5-lipoxygenase activating protein (FLAP) antagonists,

(b) Leukotriene antagonists (LTRAs) including antagonists of LTB_4, LTC_4, LTD_4, and LTE_4,

(c) Histamine receptor antagonists including H1 and H3 antagonists,

(d) α_1- and α_2-adrenoceptor agonist vasoconstrictor sympathomimetic agents for decongestant use,

(e) muscarinic M3 receptor antagonists or anticholinergic agents,

(f) PDE inhibitors, e.g. PDE3, PDE4 and PDE5 inhibitors,

(g) Theophylline,

(h) Sodium cromoglycate,

(i) COX inhibitors both non-selective and selective COX-1 or COX-2 inhibitors (NSAIDs),

(j) Oral and inhaled glucocorticosteroids,

(k) Monoclonal antibodies active against endogenous inflammatory entities,

(l) Anti-tumor necrosis factor (anti-TNF-α) agents,

(m) Adhesion molecule inhibitors including VLA-4 antagonists,

(n) Kinin-B_1- and B_2-receptor antagonists,

(o) Immunosuppressive agents,

(p) Inhibitors of matrix metalloproteases (MMPs),

(q) Tachykinin NK_1, NK_2 and NK_3 receptor antagonists,

(r) Elastase inhibitors,

(s) Adenosine A2a receptor agonists,

(t) Inhibitors of urokinase,

(u) Compounds that act on dopamine receptors, e.g. D2 agonists,

(v) Modulators of the NFκβ pathway, e.g. IKK inhibitors,

(w) modulators of cytokine signalling pathways such as p38 MAP kinase or syk kinase,

(x) Agents that can be classed as mucolytics or anti-tussive, and antibiotics.

14. (New) A method according to claim 12 wherein said disease, condition or disorder is selected from asthma and chronic obstructive pulmonary disease (COPD).